{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:16:39Z","timestamp":1793164599950,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.japh.2024.102319","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T11:54:31Z","timestamp":1735300471000},"page":"102319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Community pharmacy-based buprenorphine programs and pharmacists' roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: A systematic review"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-2515","authenticated-orcid":false,"given":"Smita","family":"Rawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-744X","authenticated-orcid":false,"given":"Justine W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-931X","authenticated-orcid":false,"given":"Courtney R.","family":"Yarbrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7455-7464","authenticated-orcid":false,"given":"Amanda J.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-6304","authenticated-orcid":false,"given":"Natalie D.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1682-3431","authenticated-orcid":false,"given":"Jordan W.","family":"Khail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-803X","authenticated-orcid":false,"given":"Ashley","family":"Chinchilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3821-4595","authenticated-orcid":false,"given":"Lorenzo","family":"Villa Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-3288","authenticated-orcid":false,"given":"Henry N.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2024.102319_bib1","series-title":"Drug Overdose Deaths in the United States, 2002-2022","author":"Spencer","year":"2024"},{"key":"10.1016\/j.japh.2024.102319_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"2-3","key":"10.1016\/j.japh.2024.102319_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.drugalcdep.2011.04.004","article-title":"30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California","volume":"118","author":"Grella","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/HRP.0000000000000052","article-title":"Long-term course of opioid addiction","volume":"23","author":"Hser","year":"2015","journal-title":"Harv Rev Psychiatry"},{"issue":"10182","key":"10.1016\/j.japh.2024.102319_bib6","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.japh.2024.102319_bib7","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.japh.2024.102319_bib8","series-title":"Medications for Opioid Use Disorder Save Lives","article-title":"National Academies of Sciences, Engineering, and Medicine Committee on medication-assisted treatment for opioid use disorder","year":"2019"},{"issue":"8","key":"10.1016\/j.japh.2024.102319_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.japh.2024.102319_bib11","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.japh.2024.102319_bib13","author":"Berk"},{"key":"10.1016\/j.japh.2024.102319_bib16","series-title":"Safety, Access, and Affordability: How the Pharmacist Role is Shifting","author":"McCoy","year":"2023"},{"issue":"8","key":"10.1016\/j.japh.2024.102319_bib17","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/jac5.1331","article-title":"Mobilizing pharmacists to address the opioid crisis: a joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy","volume":"3","author":"Coon","year":"2020","journal-title":"J\u00a0Am Coll Clin Pharm"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/jac5.1171","article-title":"Pharmacists and the opioid crisis: a narrative review of pharmacists' practice roles","volume":"3","author":"Bratberg","year":"2020","journal-title":"J\u00a0Am Coll Clin Pharm"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13722-019-0158-0","article-title":"Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders","volume":"14","author":"Bach","year":"2019","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.japh.2024.102319_bib20","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.japh.2023.06.001","article-title":"Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) act","volume":"63","author":"Adams","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jac5.1579","article-title":"Pharmacists' role in buprenorphine management for opioid use disorder: a narrative review","volume":"5","author":"Cleary","year":"2022","journal-title":"J\u00a0Am Coll Clin Pharm"},{"issue":"4","key":"10.1016\/j.japh.2024.102319_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/YCO.0000000000000943","article-title":"Pharmacist-prescriber collaborative models of care for opioid use disorder: an overview of recent research","volume":"37","author":"Cheetham","year":"2024","journal-title":"Curr Opin Psychiatry"},{"issue":"10","key":"10.1016\/j.japh.2024.102319_bib24","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.japh.2024.102319_bib25","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"205","article-title":"Assessing Risk of Bias in a Randomized Trial","author":"Higgins","year":"2019"},{"key":"10.1016\/j.japh.2024.102319_bib26","series-title":"The Joanna Briggs Institute Reviewers' Manual 2015: Methodology for JBI Scoping Reviews","first-page":"6","author":"Peters","year":"2015"},{"issue":"9","key":"10.1016\/j.japh.2024.102319_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.japh.2024.102319_bib29","series-title":"The Pocket guide to Critical appraisal","author":"Crombie","year":"1996"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1331\/JAPhA.2015.14177","article-title":"Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients","volume":"55","author":"DiPaula","year":"2015","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2208055","article-title":"Physician-delegated unobserved induction with buprenorphine in pharmacies","volume":"388","author":"Green","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.japh.2024.102319_bib32","first-page":"e255","article-title":"The Howard Street Method: A Community Pharmacy-Led low dose overlap buprenorphine initiation protocol for individuals using fentanyl","volume":"17","author":"Noel","year":"2023","journal-title":"J\u00a0Addict Med"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib33","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.japh.2021.10.002","article-title":"Ensuring buprenorphine access in rural community pharmacies to prevent overdoses","volume":"62","author":"Ostrach","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1345\/aph.1H108","article-title":"Pharmacist influence in buprenorphine treatment outcomes for opioid dependence","volume":"41","author":"Tomko","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.japh.2024.102319_bib35","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network","volume":"116","author":"Wu","year":"2021","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.japh.2024.102319_bib36","first-page":"269","article-title":"Mapping buprenorphine access at Philadelphia pharmacies","volume":"18","author":"Aronowitz","year":"2024","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.japh.2024.102319_bib37","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.japh.2022.04.019","article-title":"North Carolina community pharmacists' buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12954-022-00651-3","article-title":"Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic","volume":"19","author":"Dadiomov","year":"2022","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.japh.2024.102319_bib39","article-title":"Assessing suboxone access in community pharmacies: secret shopper model","volume":"12","author":"DiPaula","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"5","key":"10.1016\/j.japh.2024.102319_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.1077","article-title":"Barriers to buprenorphine dispensing by Medicaid-participating community retail pharmacies","volume":"5","author":"Freeman","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"6","key":"10.1016\/j.japh.2024.102319_bib41","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/add.15314","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA","volume":"116","author":"Hill","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.japh.2024.102319_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2024.102319_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 US states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2024.102319_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103321","article-title":"Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City","volume":"97","author":"Marotta","year":"2021","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2024.102319_bib45","article-title":"Association of economic and racial segregation with restricted buprenorphine dispensing in US community pharmacies","volume":"12","author":"Moon","year":"2024","journal-title":"Drug Alcohol Depend Rep"},{"issue":"5","key":"10.1016\/j.japh.2024.102319_bib46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.japh.2021.03.019","article-title":"A\u00a02019 evaluation of opioid use disorder treatment resources in rural Utah counties","volume":"61","author":"Ragsdale","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13722-022-00346-x","article-title":"Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: a secret shopper survey","volume":"17","author":"Syros","year":"2022","journal-title":"Addict Sci Clin Pract"},{"issue":"2S","key":"10.1016\/j.japh.2024.102319_bib48","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia","volume":"57","author":"Thornton","year":"2017","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"5","key":"10.1016\/j.japh.2024.102319_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.16089","article-title":"Pharmacy availability of buprenorphine for opioid use disorder treatment in the US","volume":"6","author":"Weiner","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.japh.2024.102319_bib50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.japh.2022.12.015","article-title":"Demographic and socioeconomic correlates to buprenorphine access in pharmacies","volume":"63","author":"Welsh","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib51","first-page":"68","article-title":"A\u00a0brief online training to address pharmacists' willingness to dispense buprenorphine","volume":"18","author":"Carpenter","year":"2024","journal-title":"J\u00a0Addict Med"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.japh.2022.08.027","article-title":"Understanding the role of community pharmacies in current medication for opioid use disorder care practices","volume":"63","author":"Comanici","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.japh.2024.102319_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the US opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"5","key":"10.1016\/j.japh.2024.102319_bib55","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.sapharm.2024.02.001","article-title":"\u201cI go out of my way to give them an extra smile now:\u201d A study of pharmacists who participated in respond to prevent, a community pharmacy intervention to accelerate provision of harm reduction materials","volume":"20","author":"Irwin","year":"2024","journal-title":"Res Social Adm Pharm"},{"issue":"4","key":"10.1016\/j.japh.2024.102319_bib56","first-page":"e224","article-title":"Community pharmacists' knowledge and perceptions of buprenorphine for patients with opioid use disorder","volume":"17","author":"Lehr","year":"2023","journal-title":"J\u00a0Addict Med"},{"issue":"14","key":"10.1016\/j.japh.2024.102319_bib57","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1080\/10826084.2021.1968434","article-title":"Pharmacist views regarding the prescription opioid epidemic","volume":"56","author":"Rao","year":"2021","journal-title":"Subst Use Misuse"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/29767342231215178","article-title":"Relationships between stigma, risk tolerance, and buprenorphine dispensing intentions among community-based pharmacists: results from a national sample","volume":"45","author":"Light","year":"2024","journal-title":"Subst Use Addctn J"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib59","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1521-0391.2009.00026.x","article-title":"Pharmacy willingness to partner with office-based opioid dependence treatment providers in conducting random buprenorphine pill counts","volume":"19","author":"Lofwall","year":"2010","journal-title":"Am J Addict"},{"key":"10.1016\/j.japh.2024.102319_bib60","article-title":"Factors in rural community buprenorphine dispensing","volume":"9","author":"Major","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"6","key":"10.1016\/j.japh.2024.102319_bib61","doi-asserted-by":"crossref","first-page":"302","DOI":"10.9740\/mhc.n183649","article-title":"Knowledge, attitudes, and professional practices versus personal beliefs of pharmacists regarding chemically dependent patients","volume":"3","author":"Tomko","year":"2013","journal-title":"Ment Health Clin"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1331\/1544345052843200","article-title":"Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine\/naloxone to patients with opioid dependence","volume":"45","author":"Raisch","year":"2005","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.japh.2024.102319_bib63","article-title":"Rural community pharmacist willingness to dispense Suboxone\u00ae-A secret shopper investigation in South-Central Appalachia","volume":"4","author":"Trull","year":"2021","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"4","key":"10.1016\/j.japh.2024.102319_bib64","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/08897077.2020.1809605","article-title":"The relationship between knowledge, attitudes, and practices of community pharmacists regarding persons with substance use disorders","volume":"42","author":"Rao","year":"2021","journal-title":"Subst Abus"},{"issue":"6","key":"10.1016\/j.japh.2024.102319_bib65","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.japh.2020.06.008","article-title":"Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: a descriptive analysis","volume":"60","author":"Salwan","year":"2020","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.japh.2024.102319_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"'Red flags' and 'red Tape': telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"5","key":"10.1016\/j.japh.2024.102319_bib67","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.japh.2023.06.010","article-title":"Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine\/naloxone for opioid use disorder","volume":"63","author":"Zalmai","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib68","first-page":"95","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.japh.2024.102319_bib69","article-title":"Pharmacy-based expansion of buprenorphine access","volume":"157","author":"Clark","year":"2024","journal-title":"J\u00a0Subst Use Addict Treat"},{"issue":"5","key":"10.1016\/j.japh.2024.102319_bib70","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ajhp\/zxaa390","article-title":"Medicaid reimbursement for pharmacist services: a strategy for the pharmacy profession","volume":"78","author":"Schweitzer","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.japh.2020.09.009","article-title":"Reimbursement for pharmacist-provided health care services: a multistate review","volume":"61","author":"Nguyen","year":"2021","journal-title":"J\u00a0Am Pharm Assoc"},{"key":"10.1016\/j.japh.2024.102319_bib73","author":"Muoio"},{"key":"10.1016\/j.japh.2024.102319_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104381","article-title":"Buprenorphine dispensing before and after the April 2021 X-Waiver exemptions: an interrupted time series analysis","volume":"126","author":"Roy","year":"2024","journal-title":"Int J Drug Policy"},{"issue":"5","key":"10.1016\/j.japh.2024.102319_bib75","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1377\/hlthaff.2022.01513","article-title":"Buprenorphine treatment for opioid use disorder: comparison of insurance restrictions, 2017\u201321","volume":"42","author":"Andraka-Christou","year":"2023","journal-title":"Health Aff"},{"issue":"6","key":"10.1016\/j.japh.2024.102319_bib76","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.1757","article-title":"Buprenorphine use trends following removal of prior authorization policies for the treatment of opioid use disorder in 2 state Medicaid programs","volume":"3","author":"Keshwani","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"4","key":"10.1016\/j.japh.2024.102319_bib77","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/08897077231203849","article-title":"Research priorities for expansion of opioid use disorder treatment in the community pharmacy","volume":"44","author":"Jarrett","year":"2023","journal-title":"Subst Abus"},{"issue":"8","key":"10.1016\/j.japh.2024.102319_bib78","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2839","article-title":"Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US","volume":"3","author":"Qato","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"2","key":"10.1016\/j.japh.2024.102319_bib79","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.japh.2024.01.013","article-title":"Addressing buprenorphine supply barriers: a guidance commentary","volume":"64","author":"Khail","year":"2024","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"4","key":"10.1016\/j.japh.2024.102319_bib80","first-page":"272","article-title":"DEA disconnect leads to buprenorphine bottlenecks","volume":"15","author":"Ostrach","year":"2021","journal-title":"J\u00a0Addict Med"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib81","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13690-024-01287-4","article-title":"Protocol for the development of a consensus practice guideline to address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy","volume":"82","author":"Varisco","year":"2024","journal-title":"Arch Public Health"},{"issue":"24","key":"10.1016\/j.japh.2024.102319_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/adaw.32395","article-title":"Many buprenorphine prescribers don't take Medicaid or uninsured patients","volume":"31","author":"Knopf","year":"2019","journal-title":"Alcohol Drug Abus Wkly"},{"key":"10.1016\/j.japh.2024.102319_bib83","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsat.2019.08.001","article-title":"Price elasticity of demand for buprenorphine\/naloxone prescriptions","volume":"106","author":"McClellan","year":"2019","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"4","key":"10.1016\/j.japh.2024.102319_bib84","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment","volume":"55","author":"Wen","year":"2017","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.japh.2024.102319_bib85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jval.2023.10.005","article-title":"Characteristics of prescription drug fills using pharmacy-pharmacy benefit manager discount programs: the \u201cGoodRx\u201d model","volume":"27","author":"Curran","year":"2024","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.japh.2024.102319_bib87","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1377\/hlthaff.2016.0623","article-title":"Survey highlights differences in Medicaid coverage for substance use treatment and opioid use disorder medications","volume":"35","author":"Grogan","year":"2016","journal-title":"Health Aff"},{"issue":"11","key":"10.1016\/j.japh.2024.102319_bib88","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.4001","article-title":"Coverage and prior authorization policies for medications for opioid use disorder in Medicaid managed care","volume":"3","author":"Abraham","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"6","key":"10.1016\/j.japh.2024.102319_bib89","first-page":"616","article-title":"Medicaid prescription cap policies: another structural barrier to medication for opioid use disorder","volume":"16","author":"Hughto","year":"2022","journal-title":"J\u00a0Addict Med"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124003509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124003509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:39:08Z","timestamp":1741639148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319124003509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1544319124003509"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.102319","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Community pharmacy-based buprenorphine programs and pharmacists' roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.102319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102319"}}